JP2022534794A - 関節リウマチを有する対象における疼痛を治療するための組成物および方法 - Google Patents

関節リウマチを有する対象における疼痛を治療するための組成物および方法 Download PDF

Info

Publication number
JP2022534794A
JP2022534794A JP2021572280A JP2021572280A JP2022534794A JP 2022534794 A JP2022534794 A JP 2022534794A JP 2021572280 A JP2021572280 A JP 2021572280A JP 2021572280 A JP2021572280 A JP 2021572280A JP 2022534794 A JP2022534794 A JP 2022534794A
Authority
JP
Japan
Prior art keywords
antibody
subject
seq
dmard
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021572280A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022534794A5 (https=
JPWO2020247461A5 (https=
Inventor
ステファノ・フィオーレ
スーザン・ボクレイジ
トシオ・キムラ
グレゴリー・セント・ジョン
ウェンフイ・ウェイ
ヴィヴィアン・バイカーク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2022534794A publication Critical patent/JP2022534794A/ja
Publication of JP2022534794A5 publication Critical patent/JP2022534794A5/ja
Publication of JPWO2020247461A5 publication Critical patent/JPWO2020247461A5/ja
Priority to JP2025061581A priority Critical patent/JP2025134086A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2021572280A 2019-06-04 2020-06-03 関節リウマチを有する対象における疼痛を治療するための組成物および方法 Pending JP2022534794A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025061581A JP2025134086A (ja) 2019-06-04 2025-04-03 関節リウマチを有する対象における疼痛を治療するための組成物および方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962857247P 2019-06-04 2019-06-04
US62/857,247 2019-06-04
US201962930966P 2019-11-05 2019-11-05
US62/930,966 2019-11-05
EP20305191.7 2020-02-27
EP20305191 2020-02-27
PCT/US2020/035871 WO2020247461A1 (en) 2019-06-04 2020-06-03 Compositions and methods for treating pain in subj ects with rheumatoid arthritis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025061581A Division JP2025134086A (ja) 2019-06-04 2025-04-03 関節リウマチを有する対象における疼痛を治療するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2022534794A true JP2022534794A (ja) 2022-08-03
JP2022534794A5 JP2022534794A5 (https=) 2023-06-07
JPWO2020247461A5 JPWO2020247461A5 (https=) 2023-06-07

Family

ID=71842803

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021572280A Pending JP2022534794A (ja) 2019-06-04 2020-06-03 関節リウマチを有する対象における疼痛を治療するための組成物および方法
JP2025061581A Pending JP2025134086A (ja) 2019-06-04 2025-04-03 関節リウマチを有する対象における疼痛を治療するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025061581A Pending JP2025134086A (ja) 2019-06-04 2025-04-03 関節リウマチを有する対象における疼痛を治療するための組成物および方法

Country Status (14)

Country Link
US (2) US12297279B2 (https=)
EP (1) EP3980459A1 (https=)
JP (2) JP2022534794A (https=)
KR (1) KR20230061198A (https=)
CN (1) CN115667301A (https=)
AU (1) AU2020288561A1 (https=)
BR (1) BR112021024445A2 (https=)
CA (1) CA3142710A1 (https=)
CO (1) CO2021017737A2 (https=)
IL (1) IL288573A (https=)
MA (1) MA56116A (https=)
MX (1) MX2021014892A (https=)
TW (1) TW202110892A (https=)
WO (1) WO2020247461A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020261431A1 (en) 2019-04-24 2021-12-09 Regeneron Pharmaceuticals, Inc. Methods of diagnosis and treatment of rheumatoid arthritis
EP3980459A1 (en) 2019-06-04 2022-04-13 Sanofi Biotechnology Compositions and methods for treating pain in subj ects with rheumatoid arthritis
WO2023196838A1 (en) * 2022-04-06 2023-10-12 Sanofi Biotechnology Compositions and methods for treating polymyalgia rheumatica by administering an il‑6r antagonist

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016539125A (ja) * 2013-11-22 2016-12-15 サノフィ・バイオテクノロジー 関節リウマチを治療するための組成物およびこれを使用する方法
JP2019507775A (ja) * 2016-03-07 2019-03-22 サノフィ・バイオテクノロジー 関節リウマチを処置するための組成物及び方法

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5432103A (en) 1977-08-16 1979-03-09 Nissan Motor Co Ltd Preparing apparatus for composite molten metal containing solid particles in dispersed state
JPS5870649A (ja) 1981-10-22 1983-04-27 Toyota Motor Corp ダイバ−シテイ受信システム
JPS6122018A (ja) 1984-07-06 1986-01-30 Green Cross Corp:The 癌免疫療法増強剤
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
US5670373A (en) 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
US5171840A (en) 1988-01-22 1992-12-15 Tadamitsu Kishimoto Receptor protein for human B cell stimulatory factor-2
US5216128A (en) 1989-06-01 1993-06-01 Yeda Research And Development Co., Ltd. IFN-β2/IL-6 receptor its preparation and pharmaceutical compositions containing it
JP2998976B2 (ja) 1989-07-20 2000-01-17 忠三 岸本 ヒトインタ―ロイキン―６レセプターに対する抗体
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5016784A (en) 1990-02-15 1991-05-21 Dexus Research Inc. Applicator for highly reactive materials
EP1097945B1 (en) 1991-03-18 2007-07-04 New York University Monoclonal and chimeric antibody specific for human tumor necrosis factor
EP0628639B1 (en) 1991-04-25 1999-06-23 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
US5215534A (en) 1991-12-02 1993-06-01 Lawrence De Harde Safety syringe system
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
FR2694767B1 (fr) 1992-08-13 1994-10-21 Innotherapie Lab Sa Anticorps monoclonaux anti-IL6R, et leurs applications.
KR100232688B1 (ko) 1992-09-15 1999-12-01 스코트 쥐. 홀퀴스트 종양 괴사 인자 길항제를 함유하는 tnf-의존성 염증 치료용 제약 조성물
CA2147466A1 (en) 1992-10-20 1994-04-28 Just P. J. Brakenhoff Interleukin-6 receptor antagonists
US5888511A (en) 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
US5888510A (en) 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
AU7967294A (en) 1993-10-06 1995-05-01 Board Of Regents, The University Of Texas System A monoclonal anti-human il-6 receptor antibody
PT783893E (pt) 1994-10-07 2012-05-24 Chugai Pharmaceutical Co Ltd Inibição do crescimento anormal das células sinoviais usando antagonistas de il-6 como componente ativo
CN1306963C (zh) 1994-10-21 2007-03-28 岸本忠三 用于治疗il－6产生所致疾病的药物组合物
EP0800829B2 (en) 1994-12-29 2012-07-25 Chugai Seiyaku Kabushiki Kaisha Use of a pm-1 antibody or of a mh 166 antibody for enhancing the anti-tumor effect of cisplatin or carboplatin
ES2264135T3 (es) 1995-02-13 2006-12-16 Chugai Seiyaku Kabushiki Kaisha Inhibidor de la descomposicion de proteinas musculares que contienen anticuerpos frente al receptor de il-6.
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
ZA971600B (en) 1996-02-26 1997-09-22 Merck & Co Inc Treatment of macular edema.
DK0923941T3 (da) 1996-06-27 2006-09-18 Chugai Pharmaceutical Co Ltd Midler mod myelom der skal anvendes sammen med nitrogensennepantitumormidler
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
AU747883B2 (en) 1997-08-15 2002-05-30 Chugai Seiyaku Kabushiki Kaisha Preventives and/or remedies for systemic lupus erythematosus containing anti-IL-6 receptor antibody as the active ingredient
US20020187150A1 (en) 1997-08-15 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
DK1074268T3 (da) 1998-03-17 2008-04-28 Chugai Pharmaceutical Co Ltd IL-6-receptorantagonistantistofholdige forebyggende eller terapeutiske midler mod inflammatoriske tarmsygdomme
ATE350060T1 (de) 1998-08-24 2007-01-15 Chugai Pharmaceutical Co Ltd Mittel zur vorbeugung oder behandlung von pankreatitis die anti-il-6 receptor antikörper als aktive komponente enthalten
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
US6670373B1 (en) 1999-10-07 2003-12-30 Eli Lilly And Company Compounds and method for inhibiting MRP1
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US8632778B2 (en) 2000-08-11 2014-01-21 Chugai Seiyaku Kabushiki Kaisha Stabilized anti-interleukin-6 antibody-containing preparations
US7148197B2 (en) 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
EP1327681A4 (en) 2000-10-20 2004-09-01 Chugai Pharmaceutical Co Ltd Degraded agonist antibodies
DE60133029T2 (de) 2000-10-25 2009-03-12 Chugai Seiyaku K.K. Mittel zur prävention oder behandlung von psoriasis mit einem il-6-antagonist als wirkstoff
WO2002036165A1 (fr) 2000-10-27 2002-05-10 Chugai Seiyaku Kabushiki Kaisha Agent à base d'antagoniste d'il-6, faisant baisser le niveau des mmp-3 dans le sang
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
CA2454587C (en) 2001-07-25 2012-11-13 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
BRPI0214168B8 (pt) 2001-11-14 2021-05-25 Centocor Inc anticorpos anti-il-6, moléculas de ácido nucleico codificando os mesmos, vetores compreendendo as referidas moléculas, composições e formulações compreendendo os referidos anticorpos, bem como métodos de produção dos mesmos
AU2003211990A1 (en) 2002-02-14 2003-09-04 Chugai Seiyaku Kabushiki Kaisha Antibody-containing solution pharmaceuticals
US20060275294A1 (en) 2002-08-22 2006-12-07 Omoigui Osemwota S Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer
US20060078533A1 (en) 2004-10-12 2006-04-13 Omoigui Osemwota S Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer
US20060078531A1 (en) 2004-10-12 2006-04-13 Osemwota Sota Method of prevention and treatment of atherosclerosis, peripheral vascular disease, coronary artery disease, and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease
US20060078532A1 (en) 2004-10-12 2006-04-13 Omoigui Osemwota S Method of prevention and treatment of Atherosclerosis, Peripheral vascular disease, Coronary artery disease, aging and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
CN1798575A (zh) 2003-04-04 2006-07-05 健泰科生物技术公司 高浓度抗体和蛋白制剂
EP2062916A3 (en) 2003-04-09 2009-08-19 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a TNF-Alpha inhibitor
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
EP1673396A1 (en) 2003-09-22 2006-06-28 BioVation GmbH & Co.KG. Use of antibodies for reducing the biological effectiveness of il-6
DE10355251A1 (de) 2003-11-26 2005-06-23 Merck Patent Gmbh Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
US8617550B2 (en) 2003-12-19 2013-12-31 Chugai Seiyaku Kabushiki Kaisha Treatment of vasculitis with IL-6 antagonist
BRPI0506679A (pt) 2004-02-11 2007-05-15 Warner Lambert Co métodos de tratar osteoartrite com antagonistas de il-6
CN1989439B (zh) 2004-05-06 2010-12-29 美国政府健康及人类服务部 治疗葡萄膜炎的方法以及组合物
EA014226B1 (ru) 2004-07-26 2010-10-29 Байоджен Айдек Ма Инк. Антитела к cd154, их фрагменты и способы применения антител и фрагментов
US20070036788A1 (en) 2004-09-22 2007-02-15 Ahmed Sheriff Use of a compound for reducing the biological effectiveness of il-6
WO2006046661A1 (ja) 2004-10-28 2006-05-04 Osaka University インターロイキン－６阻害剤
EP1828250A2 (en) 2004-12-16 2007-09-05 Genentech, Inc. Methods for treating autoimmune disorders
CN102961746B (zh) 2005-05-16 2016-06-15 艾伯维生物技术有限公司 TNFα抑制剂治疗腐蚀性多关节炎的用途
JPWO2007013168A1 (ja) 2005-07-29 2009-02-05 富士通株式会社 Ｒｆタグ及びｒｆタグを製造する方法
CN101312744A (zh) 2005-11-22 2008-11-26 惠氏公司 免疫球蛋白融合蛋白制剂
CN101326195B9 (zh) 2005-12-13 2022-11-11 伊莱利利公司 抗il-17抗体
US20070143168A1 (en) 2005-12-19 2007-06-21 Lucent Technologies Inc. Meeting scheduling service
US20080131374A1 (en) 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
ES2398076T3 (es) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
BRPI0713421A2 (pt) 2006-06-14 2012-03-13 Imclone Systems Incorporated Formulação liofolizada, formulação aquosa adequada para a liofilização, e, métodos para estabilizar am anticorpo e para tratar um mamífero
EP2057191A1 (en) 2006-08-18 2009-05-13 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
US20100129354A1 (en) 2006-10-27 2010-05-27 Ablynx N.V. Intranasal delivery of polypeptides and proteins
AU2008255352B2 (en) 2007-05-31 2014-05-22 Genmab A/S Stable IgG4 antibodies
EP2206775B1 (en) 2007-09-26 2016-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-il-6 receptor antibody
WO2009095489A2 (en) 2008-02-01 2009-08-06 Ablynx N.V. Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
WO2009109584A1 (en) 2008-03-07 2009-09-11 Ferring International Center S. A. ANTIBODY BINDING ONLY TO IL6-sIL6R COMPLEX
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
WO2009140348A2 (en) 2008-05-13 2009-11-19 Novimmune Sa Anti-il-6/il-6r antibodies and methods of use thereof
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
JP4885308B2 (ja) 2009-03-19 2012-02-29 中外製薬株式会社 改良された抗体分子を含有する製剤
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
JP5607736B2 (ja) 2009-07-07 2014-10-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎ウイルスプロテアーゼ阻害剤のための医薬組成物
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
KR20130065662A (ko) 2010-05-07 2013-06-19 조마 테크놀로지 리미티드 ⅠＬ-1β 관련 병태의 치료 방법
US9427531B2 (en) 2010-06-28 2016-08-30 Sanofi-Aventis Deutschland Gmbh Auto-injector
US9261526B2 (en) 2010-08-26 2016-02-16 Blast Motion Inc. Fitting system for sporting equipment
TWI603738B (zh) 2010-11-08 2017-11-01 建南德克公司 皮下投予抗－ｉｌ－６受體抗體
US8440890B1 (en) 2011-03-09 2013-05-14 Pioneer Hi Bred International Inc Maize variety inbred PH1D0D
CA2746171C (en) 2011-07-13 2018-11-06 William Jani Retrievable stimulation frac (rsf) plug
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US9943594B2 (en) * 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
CN103947096B (zh) 2011-10-21 2016-09-21 Abb研究有限公司 用于检测ac/dc转换器中失效整流器的方法和系统
US9248242B2 (en) 2012-04-20 2016-02-02 Safety Syringes, Inc. Anti-needle stick safety device for injection device
BR112015010360A8 (pt) 2012-11-08 2018-01-16 Eleven Biotherapeutics Inc antagonistas de il-6 e utilização dos mesmos.
US20140155827A1 (en) 2012-12-03 2014-06-05 Mylan, Inc. Medicament information system and method
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
SG11201601625UA (en) 2013-09-11 2016-04-28 Glenn Abrahmsohn Hypertonic antimicrobial therapeutic compositions
JP6343011B2 (ja) 2013-10-07 2018-06-13 プレステージ バイオファーマ プライベート リミテッド 抗体発現用バイシストロニック発現ベクター及びそれを用いた抗体の生産方法
ES2799439T3 (es) 2013-11-22 2020-12-17 Sanofi Biotechnology Composiciones para el tratamiento de la artritis reumatoide y métodos de uso de las mismas
IL295414B2 (en) 2014-03-27 2026-02-01 Takeda Pharmaceuticals Co Compositions and methods for treating macular edema due to diabetes
EP3152235B1 (en) 2014-05-29 2021-08-25 MacroGenics, Inc. Tri-specific binding molecules and methods of use thereof
AU2015317905A1 (en) 2014-09-16 2017-03-16 Regeneron Pharmaceuticals, Inc. Compositions for improving the health related quality of life of rheumatoid arthritis patients
TW201723174A (zh) 2015-09-03 2017-07-01 持田製藥股份有限公司 重組蛋白質的製造方法
IL319993A (en) 2015-11-03 2025-06-01 Sanofi Biotechnology Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same
WO2017106312A1 (en) 2015-12-18 2017-06-22 Drexel University Methods of modulating levels of il-6 and pd-l1
ES2642723B1 (es) 2016-05-12 2018-10-22 Servizo Galego De Saúde (Sergas) Uso de los niveles de anticuerpos anti-CD26 como biomarcadores de enfermedades autoinmunes y/o inflamatorias.
WO2018007442A1 (en) 2016-07-06 2018-01-11 Ablynx N.V. Treatment of il-6r related diseases
AU2019329958B2 (en) 2018-08-29 2025-05-29 Regeneron Pharmaceuticals, Inc. Methods and compositions for treating subjects having rheumatoid arthritis
CH715771A2 (de) 2019-01-23 2020-07-31 Pedretti Mauro Verfahren und Vorrichtung zum Speichern von Energie.
BR112021014377A2 (pt) 2019-01-31 2021-12-28 Regeneron Pharma Composições e métodos para o tratamento de artrite idiopática juvenil
AU2020261431A1 (en) 2019-04-24 2021-12-09 Regeneron Pharmaceuticals, Inc. Methods of diagnosis and treatment of rheumatoid arthritis
EP3980459A1 (en) 2019-06-04 2022-04-13 Sanofi Biotechnology Compositions and methods for treating pain in subj ects with rheumatoid arthritis
BR112021025060A2 (pt) 2019-06-12 2022-02-22 Regeneron Pharma Dosagem modificada de tocilizumab subcutâneo para artrite reumatóide
US12135885B2 (en) 2020-01-31 2024-11-05 Hewlett Packard Enterprise Development Lp Virtual storage policies for virtual persistent volumes
IL298088A (en) 2020-05-26 2023-01-01 Sanofi Biotechnology The compositions containing an antibody against the interleukin-6 receptor for the treatment of rheumatoid arthritis and methods of using them
JP7841752B2 (ja) 2020-05-29 2026-04-07 サノフィ・バイオテクノロジー 関節リウマチを有する対象における非炎症性疼痛を治療するための組成物および方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016539125A (ja) * 2013-11-22 2016-12-15 サノフィ・バイオテクノロジー 関節リウマチを治療するための組成物およびこれを使用する方法
JP2019507775A (ja) * 2016-03-07 2019-03-22 サノフィ・バイオテクノロジー 関節リウマチを処置するための組成物及び方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MARIA GABRIELLA RAIMONDO ET AL.: "Profile of sarilumab and its potential in the treatment of rheumatoid arthritis", DRUG DESIGN, DEVELOPMENT AND THERAPY, vol. 11, JPN6024010935, 2017, pages 1593 - 1603, ISSN: 0005622407 *

Also Published As

Publication number Publication date
IL288573A (en) 2022-02-01
MA56116A (fr) 2022-04-13
KR20230061198A (ko) 2023-05-08
TW202110892A (zh) 2021-03-16
AU2020288561A1 (en) 2021-12-23
CN115667301A (zh) 2023-01-31
US20200399380A1 (en) 2020-12-24
CA3142710A1 (en) 2020-12-10
US20250333522A1 (en) 2025-10-30
JP2025134086A (ja) 2025-09-16
WO2020247461A1 (en) 2020-12-10
US12297279B2 (en) 2025-05-13
EP3980459A1 (en) 2022-04-13
BR112021024445A2 (pt) 2022-02-15
MX2021014892A (es) 2022-06-27
CO2021017737A2 (es) 2022-05-20

Similar Documents

Publication Publication Date Title
US8192741B2 (en) Method of treating rheumatoid arthritis with an anti-IL-6R antibody
TWI613215B (zh) 抗－大－內皮素－１（ｂｉｇ－ｅｔ－１）抗體及其用途
US20250333522A1 (en) Compositions and methods for treating pain in subjects with rheumatoid arthritis
MX2014004398A (es) Composiciones para el tratamiento de la artritis reumatoide y metodos para su uso.
AU2019329958B2 (en) Methods and compositions for treating subjects having rheumatoid arthritis
JP2024161517A (ja) 若年性特発性関節炎を治療するための抗ｉｌ－６受容体抗体
JP2026032195A (ja) 関節リウマチのための皮下トシリズマブの改良された投薬量
JP7841752B2 (ja) 関節リウマチを有する対象における非炎症性疼痛を治療するための組成物および方法
US20230174657A1 (en) Compositions comprising an antibody against interleukin-6 receptor for the treatment of rheumatoid arthritis and methods of using same
RU2853717C1 (ru) Композиции и способы лечения невоспалительной боли у субъектов с ревматоидным артритом
RU2853717C9 (ru) Композиции и способы лечения невоспалительной боли у субъектов с ревматоидным артритом
TW202608479A (zh) 治療具有類風濕性關節炎的個體中疼痛之組成物及方法
RU2822089C2 (ru) Антитело к рецептору il-6 для лечения ювенильного идиопатического артрита
US20230272118A1 (en) Dosing Regimens for Mitigation of Cytokine Release Syndrome

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230530

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230530

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240326

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240826

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250403

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20250417

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250403

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250417